Nivolumab Associated With Better QoL Than Dacarbazine for Patients with Advanced Melanoma

Share this content:
Nivolumab improves HRQoL of patients with advanced melanoma, in contrast to dacarbazine.
Nivolumab improves HRQoL of patients with advanced melanoma, in contrast to dacarbazine.

Nivolumab improves health-related quality of life (HRQoL) of patients with advanced melanoma, in contrast to dacarbazine, according to a study published in the Annals of Oncology.1

The authors evaluated the HRQoL of patients enrolled to CheckMate 066, a phase 3 study that contrasted the efficacy of nivolumab with that of dacarbazine, for patients with untreated, unresectable, or metastatic melanoma.

Throughout study treatment, 65% of patients receiving dacarbazine and 70% of patients receiving nivolumab completed quality of life questionnaires. Baseline HRQoL scores were similar, though at several points after baseline, there was a meaningful difference in favor of nivolumab.

HRQoL of patients in the nivolumab group deteriorated later than HRQoL of those who received dacarbazine.

RELATED: Skills Training Program for Patients, Partners May Improve Melanoma Detection

The authors concluded that HRQoL of patients with advanced melanoma is superior when nivolumab, rather than dacarbazine, is administered.

HRQoL was measured using the European Organisation for Research and Treatment of Care (EORTC) Core Quality of Life Questionnaire (QLQ-C30), as well as the EuroQoL 5 Dimensions Questionnaire (EQ-5D).


  1. Long GV, Atkinson V, Ascierto PA, et al. Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase 3 checkmate 066 study. Ann Oncol. 12 Jul 2016. doi: 10.1093/annonc/mdw265 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs